Dr. Saman Honarnejad member of Drug Repurposing Advisory Board at Oncode institute

Dr. Saman Honarnejad, Director of Drug Discovery at Pivot Park Screening Centre has been appointed as an external member of the Drug Repurposing Advisory Board at Oncode Institute.

Oncode is an independent institute where the best fundamental cancer researchers in the Netherlands come together to bring their research discoveries into the clinic faster. Along with performing vital basic research, Oncode is specialized in cooperating with third parties to guide its scientists’ discoveries towards translational and clinical research and novel diagnostics, drugs, and treatments.

Pivot Park Screening Centre (PPSC) is proud to announce contributing to this effort as an external member of the Drug Repurposing Advisory Board. “PPSC’s mission as an early drug discovery service provider is to accelerate the discovery of new medicines for a healthier society.  The Drug Repurposing Program at the Oncode Institute not only allows rapid testing of novel therapeutic hypothesis, but also facilitates de-risked drug discovery with the goal of bringing new medicines to patients faster and as such, it fits very well with our mission as a company” says Dr. Saman Honarnejad, Director of Drug Discovery at PPSC and member of Drug Repurposing Advisory Board at Oncode Institute.

“Besides Early Drug Discovery-services for Pharma & Biotech, PPSC is also heavily involved in selection of crowd-sourced screening proposals across various target classes and disease areas in the European Lead Factory. Its know-how and extensive experience in tailored Assay Development and hit finding through ultra-High Throughput Screening adds a significant value to the Drug Repurposing Program at the Oncode Institute and we are happy to benefit from PPSC’s contributions” says Prof. Mario van der Stelt, Chair of Molecular Physiology at Leiden University and Drug Repurposing Advisory Board at Oncode Institute.

Development of new medicines is complex, time intensive, costly, and associated with a high degree of attrition. The 20 largest pharmaceutical companies combined spend about $60 billion each year on drug development, and the estimated average cost of marketing a single new drug including failed ones is $2.6 billion – a 140% increase over the past decade1. This sustainability crisis is a huge burden on the pharmaceutical and health care industry and patients with unmet medical needs.

Lack of safety and efficacy at different stages of drug development are the largest sources of high attrition rates. Nevertheless, repurposing marketed drugs that are in clinical use and drug candidates that were abandoned for given disease indications to tackle other diseases is an increasingly attractive approach with potentially lower development costs and timelines.

To support researchers in bringing novel therapeutic applications to the patient at affordable costs in shorter timelines, the Drug Repurposing Program at the Oncode Institute enables all Oncode researchers to have access to the next generation Drug Repurposing library, containing more than 6.000 drugs in various stages of clinical development including abandoned, off-patent and launched ones.

For more information about Oncode Institute, please visit https://www.oncode.nl/

[1] https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/the-pursuit-of-excellence-in-new-drug-development

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.